



# Anoikis-related gene signatures predict prognosis of lung adenocarcinoma patients and reveal immune infiltration

Zhikang Liu<sup>1,2</sup>, Min Zhang<sup>1,2</sup>, Xiong Cao<sup>2,3</sup>, Minjie Ma<sup>2,3</sup>, Biao Han<sup>2,3</sup>

<sup>1</sup>First School of Clinical Medicine, Lanzhou University, Lanzhou, China; <sup>2</sup>Department of Thoracic Surgery, The First Hospital of Lanzhou University, Lanzhou, China; <sup>3</sup>Gansu Province International Cooperation Base for Research and Application of Key Technology of Thoracic Surgery, The First Hospital of Lanzhou University, Lanzhou, China

**Contributions:** (I) Conception and design: Z Liu, B Han; (II) Administrative support: B Han; (III) Provision of study materials or patients: X Cao; (IV) Collection and assembly of data: Z Liu, X Cao, M Ma; (V) Data analysis and interpretation: Z Liu, M Zhang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Biao Han, MM. Gansu Province International Cooperation Base for Research and Application of Key Technology of Thoracic Surgery, The First Hospital of Lanzhou University, 1 Donggang West Road, Chengguan District, Lanzhou 730000, China. Email: hanbiao66@163.com.

**Background:** Lung adenocarcinoma (LUAD), a type of lung cancer, is one of the most aggressive and deadly malignancies worldwide. Malignant tumor cells exhibit strong anti-anoikis properties to achieve distant metastasis through the circulatory system. However, more research is needed to understand how anoikis is involved in the progression, metastasis and especially the prognosis of LUAD.

**Methods:** We obtained anoikis-related genes (ARGs) from two websites, Harmonizome and Genecards, and integrated them to select and model the genes associated with LUAD prognosis. In addition, we investigated differences in the immune cell microenvironment and pathways of enrichment analysis between subtypes. We finally constructed a nomogram based on ARGs and used decision curve analysis (DCA) to demonstrate that this model could help clinicians make clinical decisions.

**Results:** Sixty-four differentially expressed genes (DEGs) were found to be associated with survival, and of these, six were chosen to build a prognostic model. The time-dependent receiver operating characteristic (ROC) curves showed that the model had a satisfactory predictive ability. Enrichment analysis and immune microenvironment analysis revealed that the immune status and drug sensitivity of populations at high and low risk were different. We integrated the clinicopathological features of LUAD with the risk score to build the nomogram. The nomogram was shown to be a good predictor of short- and long-term survival in LUAD patients through DCA analysis.

**Conclusions:** This new model based on six ARGs and nomograms in our study could help patients with LUAD develop personalized treatment plans.

**Keywords:** Anoikis; prognosis; model; bioinformatics; lung adenocarcinoma (LUAD)

Submitted Nov 28, 2023. Accepted for publication Feb 19, 2024. Published online Apr 12, 2024.

doi: 10.21037/tcr-23-2185

**View this article at:** <https://dx.doi.org/10.21037/tcr-23-2185>

## Introduction

The second most diagnosed cancer in the world is lung cancer, which is a major contributor to death among cancer patients (1). The most common type of lung cancer is lung adenocarcinoma (LUAD), which accounts for almost 40% of all lung cancers (2). Although advances in diagnosis and treatment have been made in the past decade, the total

survival rate of LUAD patients is still unsatisfactory, and the average five-year survival rate is no more than 20% (3). Consequently, it is important to find more new biomarkers to help in the prediction of prognosis in early-stage LUAD patients to enable clinicians to provide timely treatment to their patients.

Anoikis is a mode of programmed cell death (PCD)

that occurs due to loss of attachment or inappropriate attachment of tumor cells onto the extracellular matrix (ECM) and neighboring cells (4). Cancer cell resistance to anoikis is essential for cancer cell metastasis, which allows cancer cells to survive in the systemic circulation, thereby leading to the formation of secondary tumors in distant organs (5). Anoikis resistance is a key process in cancer cell metastasis in LUAD (6,7).

In our study, we explored the role and effects of anoikis-related genes (ARGs) on the prognosis of LUAD and developed an ARG-based prognostic scoring model. We also validated the associated prognostic genes using reverse transcription quantitative polymerase chain reaction (RT-qPCR). We present this article in accordance with the TRIPOD reporting checklist (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-23-2185/rc>).

## Methods

### *Sources of clinical and transcriptome data*

Transcriptome and clinical data of 226 LUAD tissues, 539 LUAD tissues and 59 normal tissues were downloaded from the Gene Expression Omnibus (GSE31210) data portal (<https://www.ncbi.nlm.nih.gov/geo/>) and The Cancer Genome Atlas (TCGA)-LUAD database (<https://portal.gdc.cancer.gov>), respectively.

### Highlight box

#### Key findings

- In this study, anoikis-related genes (ARGs) were used to construct a risk model to predict the survival and prognosis of lung adenocarcinoma (LUAD) patients, and it was found that this model could sufficiently predict the survival and prognosis of LUAD patients, and reverse transcription quantitative polymerase chain reaction was used for verification.

#### What is known and what is new?

- Anoikis is a programmed cell death mode, and ARGs have been found to have a catalytic effect in lung adenocarcinoma, gastrointestinal and other tumors.
- Our study established a model that can sufficiently predict the prognosis of LUAD patients.

#### What is the implication, and what should change now?

- Our study provides potential therapeutic targets for early treatment of LUAD patients and improves early prognosis of LUAD patients.

### *Anoikis gene acquisition*

We downloaded 469 ARGs from the Harmonizome portals (8) and GeneCards databases (9) (<https://www.genecards.org>). Furthermore, we identified 129 differentially expressed genes (DEGs) in the TCGA-LUAD cohort by the “limma” R package.

### *Consensus clustering*

We applied the k-means method and consensus clustering to identify the different anoikis-related modes associated with the expressed anoikis regulators. Then, we verified the reliability of the clustering by unified modal approximation and projection (UMAP) using the “ggplot2” R package.

### *Gene functional enrichment analysis*

“c2.cp.kegg.v2022.1.Hs.symbols.gmt” was downloaded from the Molecular Signatures Database (MsigDB) for use in the gene set variation analysis (GSVA). We used the “GSVA” R package to carry out GSVA analysis (10).

### *Prognostic model of ARGs*

Genes relevant to survival were selected by univariate Cox regression analysis; thereafter, least absolute shrinkage and selection operator (LASSO) regression analysis was performed by the “glmnet” R package, with a penalization regularization parameter  $\lambda$  being identified via 10-fold cross-validation. Thereafter, identification of core genes and calculation of the respective coefficients were performed by multivariate Cox regression models. According to the optimal  $\lambda$  values and the respective coefficients, six ARGs were selected to develop risk signatures. For each patient, the following is the risk score calculation for the new ARG signature. Risk score =  $e^{\lambda} (\dots \text{corresponding coefficients} + \dots + CDX2 \text{ expression})$ , where Coe and Exp correspond to the coefficient of risk and expression level per gene. Time-dependent receiver operating characteristic (ROC) curves and Kaplan-Meier (KM) survival curve analyses were conducted to assess the predictive power of the model. Overall, LASSO analysis and univariate Cox regression identified six anoikis-related DEGs that showed a significant correlation with overall survival (OS) in the GSE31210 cohort, which we verified in the TCGA-LUAD cohort.

### *Association of risk score with immune cell infiltration*

For the quantification of the relative proportions of infiltrating immune cells, we employed single sample gene set enrichment analysis (ssGSEA) and CIBERSORT R scripts (11). CIBERSORT was employed to estimate the percentages of all immune cell types between the low- and high-risk cohorts. For each sample, all assessed immune cell type scores were summed to be 1. Additionally, the relation of risk score values to immune infiltrating cells was explored using Spearman rank association analysis.

### *Construction and assessment of the predictive nomogram*

Risk scores and clinicopathological features were applied to construct the nomogram. The calibration charts were internally validated to certify their accuracies. The time-C indices were employed to verify the predictive properties of this nomogram. Evaluation of the net clinical benefit was performed by decision curve analysis (DCA) (12).

### *Acquisition of tumor immune single-cell information*

We obtained the immune single-cell dataset NSCLC\_GSE127465 from the Tumor Immunization Single Cell Hub (TISCH; <http://tisch.comp-genomics.org>).

### *Analysis of the expression of prognostic genes*

To confirm the expression of prognostic genes in LUAD, we implemented RT-qPCR. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Five carcinoma side normal tissue and five tumor samples were obtained from patients with individual consent waived from The First Hospital of Lanzhou University, and this study was approved by the ethics committee of The First Hospital of Lanzhou University (No.: LDYYLL2023-263). Total RNA was extracted from ten samples using TRIzol (Ambion, Austin, USA) following the manufacturer's guidelines. Subsequently, the RNA underwent reverse transcription to cDNA using the First-strand-cDNA-synthesis-kit (Servicebio, Wuhan, China) as per the provided instructions. RT-qPCR was then conducted using the 2xUniversal Blue SYBR Green qPCR Master Mix (Servicebio) according to the manufacturer's specifications. The sequences of the PCR primers can be found in [Table S1](#). GAPDH served as an internal reference gene, and expression levels were determined employing the

$2^{-\Delta\Delta Ct}$  method (13).

### *Statistical analysis*

We used R software v4.2.1 for statistical analysis and data visualization, and P values <0.05 were deemed statistically significant.


## **Results**

### *Analysis of ARGs associated with prognosis*


We downloaded a total of 640 ARGs from the GeneCards and Harmonizome portals. Then, we compared normal tissues with TCGA-LUAD and identified 129 DEGs (*Figure 1A*). Next, the "LUAD-GSE31210" cohort with a total of 17,662 retained genes was obtained by combining the TCGA-LUAD cohort with the GSE31210 cohort after removing the batch effect. Subsequently, we found that 64 of the 129 ARGs were related to survival by univariate Cox regression analysis and with statistical significance ( $P < 0.05$ ). The forest chart shows the first 32 ARGs ( $P < 0.01$ ) (*Figure 1B*). Except for *DAPK2*, *KL*, and *CEACAM8*, the remaining 29 genes were related to poor prognosis. Additionally, the network diagram revealed the relationships among the first 32 genes in terms of gene expression levels (*Figure 1C*). Moreover, copy number variants (CNVs) data were obtained from the TCGA database to determine the chromosomal alterations of these ARGs and the location of each gene on the chromosome (*Figure 1D, 1E*). We can see that the most significant "gain" of the *S100A7* change is located on chromosome 1, while the main "loss" of *CDKX2* and *KL* is located on chromosome 13 (*Figure 1E*).

### *Consistent clustering of molecular subgroups of LUAD using ARGs*

We conducted consensus clustering of 64 DEGs associated with prognosis ( $P < 0.05$ ) using the R package "ConsensusClusterPlus". Then, we observed that the cohort could be divided into two subtypes when  $k=2$  (*Figure 2A*), and prognosis was significantly different ( $P < 0.01$ ) between the 2 subtypes as revealed by OS analysis (*Figure 2B*). The result plots of UMAP and t-distributed Stochastic Neighbor Embedding (tSNE) showed that at  $k=2$ , the two clustering subtypes were clearly distinguished (*Figure 2C, 2D*). The heat map depicted in *Figure 2E* illustrates a low expression of *S100A7* in the majority of the two subtypes, suggesting




**Figure 1** Anoikis-related differential genes and associated regulatory factors in LUAD. (A) A total of 129 ARGs identified from TCGA-LUAD cohort. (B) Forest plot of the first 32 ARGs by univariate Cox regression analysis ( $P < 0.01$ ). (C) Correlation network diagram between the first 32 ARGs. (D) CNVs of 32 ARGs in TCGA-LUAD. (E) Changes in chromosomal region of ARGs. LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; ARGs, anoikis-related genes; CNVs, copy number variants; CI, confidence interval.



**Figure 2** LUAD subgroups associated with ARGs. (A) By consensus clustering a consensus matrix for k=2 is derived. (B) Overall survival analysis curves of the two subtypes ( $P < 0.001$ ). (C,D) The two subtypes were differentiated by the UMAP and tSNE through the expression of ARGs. (E) Heat map showing the expression and clinicopathologic features of the two subtypes of ARGs. (F) Different enrichment levels of the KEGG pathway between the two subtypes. LUAD, lung adenocarcinoma; ARGs, anoikis-related genes; UMAP, unified modal approximation and projection; tSNE, t-distributed stochastic neighbor embedding; KEGG, Kyoto Encyclopedia of Genes and Genomes.





**Figure 3** Gene expression and immune infiltration in two subtype groups. (A) Expression of ARGs in both subtype groups. (B) Immune infiltration of both subtype groups. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; ARGs, anoikis-related genes.


that *S100A7* may be a good prognostic factor. Finally, we used the R package “GSVA” to analyze the differences in the enrichment levels of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways between two subtypes (Figure 2F).

#### Gene-expression pattern and immune-cell infiltration in two subtypes

We can see from Figure 3A that *NTRK2*, *DAPK2*, *BDNF*, *ZEB2*, *ITGA8*, *KL*, *GDF2*, *CEACAM8*, *CLDN18* and *IRX1* expression were higher in Cluster B than in Cluster A; high expression patterns were also shown for other ARGs. Moreover, ssGSEA results showed a significantly lower proportion of activated CD4 and regulatory T cells in population B than in population A (Figure 3B); other immune cell infiltration levels were also significantly different.

#### Construction and validation of anoikis-related prognostic signatures

In the univariate Cox regression analysis, we identified seven ARGs associated with the OS rate using the LASSO analysis (Figure 4A,4B). In the ensuing multivariate Cox regression analysis, six ARGs were independently selected as predictors for the prognosis of LUAD, establishing the risk model. In Table S2, the correlation coefficients based on the six ARGs characteristic are listed. The risk score is calculated as follows: Risk score =  $(0.300 \times \text{level of } PDGFB \text{ expression}) + (0.160 \times \text{level of } HMOX1 \text{ expression}) + (0.521 \times \text{level of } GDF2 \text{ expression}) + (0.582 \times \text{level of } LDHA \text{ expression}) + (0.068 \times \text{level of } S100A7 \text{ expression}) + (0.232 \times \text{level of } CDX2 \text{ expression})$ . The data were divided into train and test groups and the samples from each group were divided into high and low-risk groups according to the



**Figure 4** Identification of anoikis-related prognostic signature. (A) LASSO analysis with cross-validation to identify six prognostic ARGs. (B) Coefficient plot of six prognostic ARGs. (C,D) KM curves for two subtype risk groups. (E,F) Time-dependent ROC curves for 1-, 3- and 5-year OS. (G) Risk score in two ARGclusters. (H) Alluvial diagram of two subtypes and living status. (I) Heat map of the expression patterns of the six ARGs. LASSO, least absolute shrinkage and selection operator; ARGs, anoikis-related genes; KM, Kaplan-Meier; ROC, receiver operating characteristic; OS, overall survival; AUC, area under curve.

median value of the risk scores. The K-M curves revealed a worse prognosis for patients in high-risk group in both the train and test groups (Figure 4C,4D). This model showed good predictive performance for the time-dependent ROC curves for OS at 1, 3, and 5 years in both the train and test groups (Figure 4E,4F). As seen in Figure 4G, the risk scores are clearly different in the two subtypes, and Figure 4H shows the differences in ARGs clusters, risk scores and life status. We visualized the expression of the six prognostic ARGs in high-risk and low-risk groups by heatmap and could see that *GDF2*, *CDX2*, *PDGFB*, *HMOX1*, *LDHA*, and *S100A7* had higher expression in the high-risk group (Figure 4I).

### ***Analysis of immune activity in LUAD***

Tumor cells may have inherent resistance to cancer therapy, often conferred by nonmalignant cells that constitute the tumor microenvironment (TME) (14). Therefore, we further investigated the TME in both high and low-risk groups, and the “CIBERSORT” R script was used to measure the relative proportion of immune cell infiltrations. Figure 5A shows the relative percentage of each immune cell that corresponds with their risk score. As seen in Figure 5B, the macrophage M0 ratio became gradually larger with higher score (R=0.24). In addition, macrophages represent a large proportion of immune cells in LUAD patients (Figure 5C). This finding suggests that targeted therapy against macrophages could be a therapeutic approach for LUAD (14). We can use the correlation plot among immune cells from LUAD patients to better understand the TME composition (Figure 5D). In addition, six genes for model construction were associated with several immune cell infiltrations (Figure 5E). Moreover, in examining the stromal cell component of the TME, assessing immune cell infiltration levels, and estimating tumor purity, we computed immune scores, stromal scores, and estimation scores for the high-risk and low-risk groups based on the estimation of expression profiling scores (Figure 5F). Finally, the potential sensitivity to clinical agents was increased for both the high and low-risk groups (Figure S1).

### ***Prognostic nomogram for patients with LUAD***

Based on the clinicopathological characteristics and risk scores of the ARGs, we developed a nomogram model that could complete the prediction of the survival probability at 1, 3 and 5 years for LUAD patients (Figure 6A). The nomogram construction relies on regression coefficients'

magnitudes for all predictors, establishing a scale that assigns scores based on each predictor's value. In instances with multiple predictors, a cumulative score is calculated, facilitating the subsequent computation of the probability of correlation with the occurrence of a clinical outcome for each patient, determined by their total score. We used calibration plot to verify the accuracy of this nomogram (Figure 6B) and decision curve analysis (DCA) to evaluate whether this strategy would benefit patients. DCA showed that this nomogram was a good predictor for predicting both short-term and long-term survival of LUAD patients (Figure 6C-6E). We can see in the nomogram that the cumulative risk curves show a gradual increase in OS risk among the LUAD patients in the high-risk and low-risk groups (Figure 6F). Figure 6G shows that the main influencing factors in the nomogram. In conclusion, the nomogram based on risk score can be a valid method for clinical prediction of prognosis in LUAD patients.

### ***Analysis of tumor immune microenvironment***

As shown in Figure 7A, 25 cell populations with 12 cell types are included in the NSCLC\_GSE127465 dataset. *HMOX1* is found mainly in malignant cells and immune cells, but is rarely expressed in fibroblasts. *PDGFB* is mainly expressed in endothelial cells, but is barely expressed in immune cells. *GDF2* and *CDX2* are barely detected in TME, *LDHA* is mainly expressed in immune cells and malignant cells. *S100A7* is barely detected in TME (Figure 7B,7C).


### ***Expression validation of the prognostic genes***

The expression of prognostic genes was analyzed in the training set (TCGA-LUAD). We observed higher expression of *PDGFB*, *HMOX1* and *GDF2* in the normal group than in the tumor group (Figure 8A). We further verified the expression trend by RT-qPCR experiments (Figure 8B).


## **Discussion**

Since patients with metastatic LUAD have a poor prognosis and a low five-year survival rate, early diagnosis is essential for improving survival time for patients with LUAD. However, although the novel prognostic model we developed with six ARGs had good predictive performance, the number of markers used is insufficient. Consequently, more screening biomarkers are urgently needed to help





**Figure 5** The immune microenvironment of LUAD tissues. (A) Relative proportions of infiltrating immune cells. (B) Correlation analysis of risk scores with the proportion of macrophage M0 in LUAD tissue. (C) Comparison of immunocytes composition between the high-risk and low-risk groups. (D) Correlation between immunocytes. (E) Correlation among immunocytes and the six ARGs. (F) Estimated scores for expression profiles of the two risk groups. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; LUAD, lung adenocarcinoma; NK cells, natural killer cells; TME, tumor microenvironment.




**Figure 6** Nomogram of LUAD patients. (A) Nomogram depended on ARGscore and clinicopathological characters. (B) A calibration plot used to validate the nomogram. (C-E) DCA curves for nomograms of OS at 1, 3 and 5 years. (F) Progression of survival probability over time is represented by the cumulative hazard curve. (G) Forest plot of multivariate Cox regression analysis of clinical characteristics as well as risk scores of LUAD patients. \*\*\*, P<0.001. LUAD, lung adenocarcinoma; ARG, anoikis-related genes; OS, overall survival; DCA, decision curve analysis; AIC, Akaike Information Criterion; pr, probability.


diagnose early LUAD and improve the survival rate of LUAD patients.

*PDGFB* is involved in the process of recruiting *PDGF* receptor  $\beta$ -positive pericytes to the vasculature (15-17).

*PDGFB* has been reported to stimulate cell proliferation, survival and migration in a variety of tumor cells, including LUAD (18). The oncoprotein *PDGFB* has been reported to be essential for cancer proliferation and migration (19).



**Figure 7** ARGs expression in LUAD TME associated cells. (A) Annotation of all cell types in GSE127465 and percentage of each cell type. (B,C) Percentage and expression of *PDGFB*, *HMOX1*, *GDF2*, *S100A7*, *LDHA* and *CDX2*. ARGs, anoikis-related genes; LUAD, lung adenocarcinoma; TME, tumor microenvironment; NSCLC, non-small cell lung cancer; GSE, Gene Expression Omnibus series; NK, natural killer.



**Figure 8** Expression validation of the prognostic genes. (A) Expression of prognostic genes in training set (TCGA-LUAD). (B) Comparison of expression differences of six genes in RT-qPCR experiment. \*,  $P < 0.05$ ; ns,  $P \geq 0.05$ . LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; RT-qPCR, reverse transcription quantitative polymerase chain reaction.

These results suggest that *PDGFB* contributes to lung adenocarcinogenesis, which was consistent with our data indicating that *PDGFB* is highly expressed in high-risk groups. Given the significant role of the oncoprotein encoded by this gene in cancer cell proliferation and metastasis, further studies on *PDGFB* have the potential for clinical application.

*HMOX1* could help promote tumor progression and metastasis in several cancers, including LUAD, and is expressed in malignant tumor cells and tumor associated

macrophages (TAM) (20). *HMOX1* is an anti-apoptotic, antioxidant and anti-inflammatory protein that promotes not only metabolic reprogramming but also antioxidant defense (21). Moreover, it is possible that *HMOX1* can promote LUAD metastasis by affecting macrophages and mitochondrial complexes (22). In our data, *HMOX1* was overexpressed in the high-risk group and the proportion of macrophages M0 increased progressively with increasing risk score, and we searched for new therapeutic approaches by investigating the effect of *HMOX1* on TAM.

*GDF2*, also known as *BMP9*, belongs to the transforming growth factor (TGF)- $\beta$  superfamily, mainly generated by the liver, and induces osteo/odontogenic differentiation of mesenchymal stem cells (MSCs) (23,24). *Alk1* is a *BMP* receptor expressed on endothelial cells (25). It has been reported that *GDF2* overexpression in LUAD tumors delays tumor growth and promotes vascular normalization in LUAD tumors, resulting in significant alterations in the TME characterized by reduced hypoxia and increased immune infiltration (26). In addition, *GDF2* has been reported to increase anoikis sensitivity in epithelial cells (27). However, studies on the role of *GDF2* in LUAD are scarce, and large-scale studies with more LUAD patients are still needed to confirm the relationship between *GDF2* and LUAD.

*LDHA* is an essential member involved in glycolysis, catalyzing the conversion of pyruvate and NADH to lactate and NAD<sup>+</sup> (28). *LDHA* tyrosine phosphorylation promotes cancer cell metabolism and tumor cell proliferation through the modulation of dysregulated NADH/NAD<sup>+</sup> redox homeostasis of fibroblast growth factor receptor 1 (FGFR1) in LUAD cells (29). The phosphorylation of *LDHA* at Y10 has been proven to enhance the invasiveness and anti-inflammatory properties of cancer cells (30). *LDHA* is an emerging anticancer target that has an important role in regulating cancer metabolism and anoikis resistance. In our data, *LDHA* was overexpressed in the high-risk group, and inhibitors targeting *LDHA* have potential for clinical application in the treatment of LUAD.

Increased *S100A7* protein expression has been described in lung cancer and correlates with poor prognosis (31), and its overexpression is significantly associated with the early stages of many cancers (32,33). However, the function of *S100A7* expression in lung cancer tissues is not clear, *S100A7* protein may act as a chemokine and serum marker for lung cancer (34). *S100A7* has also been shown to promote the transdifferentiation of adenocarcinoma to squamous carcinoma in lung cancer cells (35). In addition, *S100A7* enhances macrophage infiltration (36).

*CDX2* is a transcriptional regulator of several genes responsible for cell proliferation, differentiation and migration (37). *CDX2* expression reduction can lead to tumor metastasis (38). It has been reported that the synergistic effect of simultaneous deletion of *CDX2* and *NKX2-1* activates the metastatic program of LUAD (39). Moreover, *CDX2* expression was found to be a reliable marker for determining the colorectal origin of pulmonary metastases (40). Recent reports suggest that *CDX2* expression can be detected by RT-

PCR and immunohistochemistry in primary LUAD (41).

For these six bases, we conducted RT-qPCR validation, and the PCR results were consistent with those analyzed in our experiment, which further confirmed the therapeutic potential of these six genes in LUAD.

TME research is meaningful in that it can help physicians develop new targeted therapeutic agents and observe tumor metastasis progression. Our analysis of the immune cell composition shows a significantly higher proportion of macrophages among the high-risk group, suggesting that macrophages have a critical effect in LUAD development. In addition, both *S100A7* and *HMOX1* were associated with macrophages, and in particular, *HMOX1* showed the highest related coefficient to macrophage M0. Thus, the *HMOX1*/macrophage M0 axis may be an interesting pathway.

However, there are many limitations in this study. Due to the limited amount of data and cell-to-cell heterogeneity, we had problems calibrating predictive models and reflecting the accuracy of ARGs on the prognostic impact of LUAD patients. Moreover, the results of TME were obtained from data analysis. The role of anoikis in targeted therapy and immune microenvironment needs to be confirmed with further study.

## Conclusions

Our novel 6-ARG nomogram model can sufficiently predict the survival of patients with early-stage LUAD, while the nomogram may help to develop personalized treatment plans for patients. We are confident that this nomogram model will serve as a good predictor of the survival of patients with LUAD, and the validated gene will provide an effective therapeutic target for the treatment of LUAD.

## Acknowledgments

The authors thank AJE for their language assistance during the writing of this article.

**Funding:** This work was supported by Educational Technology Innovation Project of Gansu Province (2022B-014) and Hospital Foundation of The First Hospital of Lanzhou University (ldyyyn2021-66).

## Footnote

**Reporting Checklist:** The authors have completed the TRIPOD reporting checklist. Available at <https://tcr>.



[amegroups.com/article/view/10.21037/tcr-23-2185/rc](https://amegroups.com/article/view/10.21037/tcr-23-2185/rc)

*Peer Review File:* Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-23-2185/prf>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-23-2185/coif>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by committee ethics board of The First Hospital of Lanzhou University (No. LDYYLL2023-263) and individual consent for this retrospective analysis was waived.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209-49.
- Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. *Cell Death Dis* 2018;9:117.
- Lin JJ, Cardarella S, Lydon CA, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. *J Thorac Oncol* 2016;11:556-65.
- Zhou X, Li L, Guo X, et al. HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer. *NPJ Breast Cancer* 2022;8:7.
- Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. *Biochim Biophys Acta* 2013;1833:3481-98.
- Chunhacha P, Chanvorachote P. Roles of caveolin-1 on anoikis resistance in non small cell lung cancer. *Int J Physiol Pathophysiol Pharmacol* 2012;4:149-55.
- Prateep A, Sumkhemthong S, Karnsomwan W, et al. Avicquinone B sensitizes anoikis in human lung cancer cells. *J Biomed Sci* 2018;25:32.
- Rouillard AD, Gundersen GW, Fernandez NF, et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. *Database (Oxford)* 2016;2016:baw100.
- Rebhan M, Chalifa-Caspi V, Prilusky J, et al. GeneCards: integrating information about genes, proteins and diseases. *Trends Genet* 1997;13:163.
- Hänzelmann S, Castelo R, Guinney J. GSEA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics* 2013;14:7.
- Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods* 2015;12:453-7.
- Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. *BMC Med Inform Decis Mak* 2008;8:53.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(-Delta Delta C(T)) Method. *Methods* 2001;25:402-8.
- Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. *Nat Rev Drug Discov* 2018;17:887-904.
- Lindahl P, Johansson BR, Levéen P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. *Science* 1997;277:242-5.
- Hellström M, Kalén M, Lindahl P, et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. *Development* 1999;126:3047-55.
- Soriano P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. *Genes Dev* 1994;8:1888-96.
- Bartoschek M, Pietras K. PDGF family function and prognostic value in tumor biology. *Biochem Biophys Res Commun* 2018;503:984-90.
- Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. *Biochem Biophys Res Commun* 2007;356:323-8.
- Luu Hoang KN, Anstee JE, Arnold JN. The Diverse Roles of Heme Oxygenase-1 in Tumor Progression. *Front*

- Immunol 2021;12:658315.
21. Biswas C, Shah N, Muthu M, et al. Nuclear heme oxygenase-1 (HO-1) modulates subcellular distribution and activation of Nrf2, impacting metabolic and antioxidant defenses. *J Biol Chem* 2014;289:26882-94.
  22. Chen B, Zhang L, Zhou H, et al. HMOX1 promotes lung adenocarcinoma metastasis by affecting macrophages and mitochondrion complexes. *Front Oncol* 2022;12:978006.
  23. Chen Q, Zheng L, Zhang Y, et al. Special AT-rich sequence-binding protein 2 (Satb2) synergizes with Bmp9 and is essential for osteo/odontogenic differentiation of mouse incisor mesenchymal stem cells. *Cell Prolif* 2021;54:e13016.
  24. Song D, Zhang F, Reid RR, et al. BMP9 induces osteogenesis and adipogenesis in the immortalized human cranial suture progenitors from the patent sutures of craniosynostosis patients. *J Cell Mol Med* 2017;21:2782-95.
  25. David L, Mallet C, Mazerbourg S, et al. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. *Blood* 2007;109:1953-61.
  26. Viillard C, Audiger C, Popovic N, et al. BMP9 signaling promotes the normalization of tumor blood vessels. *Oncogene* 2020;39:2996-3014.
  27. Varadaraj A, Patel P, Serrao A, et al. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. *Neoplasia* 2015;17:826-38.
  28. Bui T, Thompson CB. Cancer's sweet tooth. *Cancer Cell* 2006;9:419-20.
  29. Fan J, Hitosugi T, Chung TW, et al. Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. *Mol Cell Biol* 2011;31:4938-50.
  30. Jin L, Chun J, Pan C, et al. Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. *Oncogene* 2017;36:3797-806.
  31. Zhang H, Wang Y, Chen Y, et al. Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. *Lung Cancer* 2007;57:37-45.
  32. Semprini S, Capon F, Bovolenta S, et al. Genomic structure, promoter characterisation and mutational analysis of the S100A7 gene: exclusion of a candidate for familial psoriasis susceptibility. *Hum Genet* 1999;104:130-4.
  33. Alowami S, Qing G, Emberley E, et al. Psoriasin (S100A7) expression is altered during skin tumorigenesis. *BMC Dermatol* 2003;3:1.
  34. Zhang H, Zhao Q, Chen Y, et al. Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. *Thorax* 2008;63:352-9.
  35. Wang R, Li Y, Hu E, et al. S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells. *Oncotarget* 2017;8:24804-14.
  36. Lu Z, Zheng S, Liu C, et al. S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis. *Clin Transl Med* 2021;11:e459.
  37. Olsen AK, Coskun M, Bzorek M, et al. Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells. *Carcinogenesis* 2013;34:1361-9.
  38. Asgari-Karchekani S, Karimian M, Mazoochi T, et al. CDX2 Protein Expression in Colorectal Cancer and Its Correlation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients. *J Gastrointest Cancer* 2020;51:844-9.
  39. Li CM, Gocheva V, Oudin MJ, et al. Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. *Genes Dev* 2015;29:1850-62.
  40. Saad RS, Cho P, Silverman JF, et al. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. *Am J Clin Pathol* 2004;122:421-7.
  41. Yatabe Y, Koga T, Mitsudomi T, et al. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. *J Pathol* 2004;203:645-52.

**Cite this article as:** Liu Z, Zhang M, Cao X, Ma M, Han B. Anoikis-related gene signatures predict prognosis of lung adenocarcinoma patients and reveal immune infiltration. *Transl Cancer Res* 2024;13(4):1861-1875. doi: 10.21037/tcr-23-2185




Figure S1 Sensitivity of high- and low-risk groups to clinical drugs

**Table S1** The primer sequences for polymerase chain reaction

| Primer   | Sequence                 |
|----------|--------------------------|
| PDGFB F  | CATGACCCGCTCCCACTCT      |
| PDGFB R  | TCCGCACAATCTCGATCTTTC    |
| HMOX1 F  | GCCAGCAACAAAGTGCAAGA     |
| HMOX1 R  | TAAGGACCCATCGGAGAAGC     |
| GDF2 F   | TGCCCTTCTTTGTTGTCTTCTC   |
| GDF2 R   | TGTCCTCCTCGTGA CTGCTCT   |
| LDHA F   | CTGTGTCTTGCTGTAGGAGC     |
| LDHA R   | AGGAATATCGACGTTTGGGTGT   |
| S100A7 F | ATTACCTCGCCGATGTCTTTGA   |
| S100A7 R | ATGGCTCTGCTTGTGGTAGTCTGT |
| CDX2 F   | TTCAGAACCGCAGAGCAAAG     |
| CDX2 R   | GGAAGACACCGGACTCAAGG     |
| GAPDH F  | CGAAGGTGGAGTCAACGGATTT   |
| GAPDH R  | ATGGGTGGAATCATATTGGAAC   |

F, forward primer; R, reverse primer.

**Table S2** Final risk scores for six prognostic genes

| ID     | coef     |
|--------|----------|
| PDGFB  | 0.300157 |
| HMOX1  | 0.160014 |
| GDF2   | 0.520881 |
| LDHA   | 0.582019 |
| S100A7 | 0.068052 |
| CDX2   | 0.232275 |